<DOC>
	<DOCNO>NCT00290940</DOCNO>
	<brief_summary>This study compare glucose lower CS-917 compare placebo 3 month treatment</brief_summary>
	<brief_title>Evaluation Glucose Lowering Effect , Safety Tolerability CS-917</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Drug naive newly diagnose type 2 diabetic subject : Never receive oral antihyperglycemic insulin therapy No oral antihyperglycemic insulin therapy 6 month since original diagnosis No insulin therapy within one year screening , exception use hospitalization use gestational diabetes No antihyperglycemic therapy three consecutive day , total seven nonconsecutive day , 8 week prior screen . HbA1C &gt; 6.7 % &lt; = 10 % screen Current insulin therapy Symptoms poorly control diabetes History diabetic ketoacidosis hyperosmolar , nonketonic coma within one year screen Serum bicarbonate &lt; = 19 meq/L Serum creatinine ( Scr ) &gt; 1.4 mg/dL ( female ) 1.5 mg/dL ( male ) Contraindication metformin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>Diabetes mellitus , Type 2</keyword>
	<keyword>High blood sugar</keyword>
	<keyword>Hyperglycemia</keyword>
	<keyword>Antihyperglycemic agent</keyword>
	<keyword>CS-917</keyword>
</DOC>